Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00742222 · ClinicalTrials.gov registry record · Phase 4
Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer
A Phase 4 study of Breast Cancer and Carcinoma, sponsored by Xoft.
- Completed
- Registry status
- Phase 4
- Development phase
- 63
- Enrollment target
- 8
- Study locations
NCT00742222: Completed Phase 4 study of Breast Cancer and Carcinoma, sponsored by Xoft.
NCT00742222 is a Phase 4 study of Breast Cancer and Carcinoma that has completed, run by Xoft. The registered enrollment target is 63 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower). The trial reports 8 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00742222, a Phase 4 study of Breast Cancer and Carcinoma, has completed, sponsored by Xoft.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 63 participants
- Enrollment target
- 8
- Study locations
Study Summary
PRINCIPAL INVESTIGATORS * Rakesh Patel, MD- Radiation Oncologist * Peter Beitsch, MD- Breast Surgeon REGISTRY DESIGN * Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in appropriately selected patients. SAMPLE SIZE AND SITES: * Approximately 400 patients may be enrolled. * Up to 100 qualified U.S. sites may participate in this registry. ENDPOINTS: 1. PRIMARY ENDPOINTS * Subcutaneous Toxicities - The incidence of signs and symptoms of subcutaneous toxicities will be recorded at the following follow-up visits; at six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year. * Skin Toxicities - Specific toxicities that can result from radiation therapy will be recorded at each follow-up visit. The Common Terminology Criteria for Adverse Events will be used and to be recorded at each follow-up visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year. * Cosmetic Outcome - Cosmetic outcome will be recorded at the following follow-up visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year. Cosmetic outcome will be assessed and graded in two ways: * Patient Quality of Life Questionnaire - A Quality of Life Questionnaire (QOL) will be completed at the following visits; at one (1) month, six (6) month, one (1) year, two (2) year, three (3) year, four (4) year, and five (5) year. 2. SECONDARY ENDPOINTS * Local-regional Breast Failure - The secondary efficacy endpoint is ipsilateral breast failure at five (5) years. This includes: * Ipsilateral recurrence within the initially treated volume. (Within the tumor bed) * Ipsilateral recurrence of cancer outside of the initially treated volume. (Elsewhere Failure) * Axillary nodal recurrence * Survival - to be recorded at each follow-up visit * Overall Survival * Disease Free S
Conditions Studied
Interventions
- RADIATION Electronic Brachytherapy
- RADIATION Intracavitary accelerated partial breast irradiation
Study Locations (8)
New Jersey
- AtlantiCare Cancer Care Institute - Galloway
- Nazha Cancer Center - Northfield
Alabama
- DCH Cancer Treatment Center - Tuscaloosa
California
- Beverly Oncology - Montebello
Florida
- Florida Radiation Oncology Group - Orange Park
Illinois
- St Elizabeth's and Memorial Cancer Center - Swansea
Missouri
- Cancer Institute of Cape Girardeau - Cape Girardeau
Texas
- Dallas Surgical Group / Northpoint Cancer Center - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 63 participants |
| Start Date | 2008-05 |
| Est. Completion | 2015-01 |
| Phase | Phase 4 |
What the finished NCT00742222 record still lists
NCT00742222 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 63 participants, a relatively small participant target, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (98% lower).
The record links to 4 conditions, with Breast Cancer appearing as the primary indexed condition, and to 2 interventions - of which Electronic Brachytherapy is the first listed.
NCT00742222 lists 8 locations in 7 states (New Jersey, Alabama, California).
Frequently Asked Questions
What is clinical trial NCT00742222 about?
NCT00742222 is a clinical study titled "Electronic Xoft Intersociety Brachytherapy Trial: Electronic Brachytherapy (EBT) For Treatment of Early Stage Breast Cancer". PRINCIPAL INVESTIGATORS * Rakesh Patel, MD- Radiation Oncologist * Peter Beitsch, MD- Breast Surgeon REGISTRY DESIGN * Multicenter, non-randomized, post market registry of intracavitary accelerated partial breast irradiation in appropriately selected patients. SAMPLE SIZE AND SITES: * Approxima...
What is the current status of trial NCT00742222?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 63 participants. The study started on 2008-05. Estimated completion is 2015-01.
What conditions does trial NCT00742222 study?
This clinical trial studies the following conditions: Breast Cancer, Carcinoma, Ductal Carcinoma In Situ, Lumpectomy.
What interventions are being tested in trial NCT00742222?
The interventions under investigation include: Electronic Brachytherapy (RADIATION), Intracavitary accelerated partial breast irradiation (RADIATION).
Who is sponsoring clinical trial NCT00742222?
This trial is sponsored by Xoft, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00742222 being conducted?
This trial has 8 study locations across Alabama, California, Florida, Illinois, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00742222's enrollment target sits among peer trials
63 727th of 1224 higher than 495 of 1,224 other Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Brain [18F]-FES PET/CT in Patients With Estrogen-Receptor Positive Breast Cancer
RECRUITING · Phase 4
-
Liposomal Bupivacaine Vs Bupivacaine with Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies
RECRUITING · Phase 4
-
Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
RECRUITING · Phase 4
-
Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Cancer
RECRUITING · Phase 4
-
CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
RECRUITING · Phase 4
-
Abemaciclib Dose Escalation to Maintain Intensity (ADE-MI)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03383575 · 63 participants · Phase 2
Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome
- NCT04870944 · 63 participants · Phase 1
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- NCT05031897 · 63 participants · Phase 2
Two Step Haplo With Radiation Conditioning
- NCT05312671 · 63 participants · Phase 2
Atezolizumab Plus Etoposide and Platinum in Small Cell Bladder Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia